Osteosarcoma & UPS-B (MFH of Bone) | Malignant Bone Tumor Treatment Guide — Cost, Top Hospitals & Success Rates | MyMedicPlus

Malignant tumours of bone arising from mesenchymal precursors represent a clinically and histologically diverse group of cancers that demand multidisciplinary management at specialist sarcoma centres. Two entities that have historically been discussed together are osteosarcoma and the tumour formerly classified as malignant fibrous histiocytoma (MFH) of bone.

WHO 2020 Reclassification: The 5th edition of the WHO Classification of Tumours: Soft Tissue and Bone Tumours (2020) formally retired the diagnosis of ‘MFH of bone,’ reclassifying these tumours as undifferentiated pleomorphic sarcoma of bone (UPS-B). This reflects decades of immunohistochemical and molecular evidence demonstrating that the original MFH category was histologically heterogeneous and did not represent a distinct fibrohistiocytic lineage. UPS-B is now defined as a high-grade sarcoma showing no identifiable line of differentiation on morphology, immunohistochemistry, or molecular analysis — a diagnosis of exclusion after other specific sarcoma subtypes have been ruled out.

Osteosarcoma remains the most common primary malignant bone tumour (excluding plasma cell myeloma), accounting for approximately 35% of all primary bone sarcomas. It is characterised by the production of osteoid by malignant stromal cells. The tumour shows a bimodal age distribution: a primary peak in the second decade of life (ages 10–20), predominantly affecting the metaphyses of long bones (distal femur, proximal tibia, proximal humerus), and a secondary peak in patients over 60 years, where osteosarcoma arises secondarily on a background of Paget’s disease of bone, prior radiation fields, or other bone abnormalities.

Both osteosarcoma and UPS-B are aggressive, high-grade tumours requiring systemic chemotherapy combined with surgical resection as the cornerstone of curative treatment. The survival landscape has been transformed by the introduction of multiagent neoadjuvant and adjuvant chemotherapy since the 1970s and 1980s.

Accurate histological and molecular classification underpins treatment selection for malignant bone tumours. The main subtypes requiring clinical distinction are as follows.

Osteosarcoma subtypes (WHO 2020):

• Conventional (central) osteosarcoma: The most common subtype (~75% of osteosarcomas), arising within the medullary cavity of long bones. Always high grade. Subtypes include osteoblastic, chondroblastic, and fibroblastic variants based on dominant matrix production.
• Telangiectatic osteosarcoma: Highly destructive, blood-filled spaces on imaging; resembles an aneurysmal bone cyst but is malignant. Responds well to neoadjuvant chemotherapy.
• Small cell osteosarcoma: Histologically similar to Ewing sarcoma but produces osteoid; requires differentiation from Ewing sarcoma by molecular testing (EWSR1/FUS rearrangements absent).
• Parosteal osteosarcoma: Low-grade tumour arising on the surface (posterior distal femur most common); surgery alone may be curative; chemotherapy not routinely indicated.
• Periosteal osteosarcoma: Intermediate grade, surface arising; predominantly chondroblastic; chemotherapy generally recommended.
• High-grade surface osteosarcoma: High grade; managed like conventional osteosarcoma.
• Secondary osteosarcoma: Arising in abnormal bone (Paget disease, fibrous dysplasia, bone infarct, post-radiation); occurs in older adults; prognosis significantly worse than primary osteosarcoma.

Undifferentiated Pleomorphic Sarcoma of Bone (UPS-B): High-grade spindle-cell and pleomorphic sarcoma without definable differentiation. Distinguished from dedifferentiated chondrosarcoma, fibrosarcoma of bone, and metastatic carcinoma by a combination of morphology, immunohistochemistry (negativity for epithelial, melanocytic, myogenic, neural markers), and molecular testing. Clinically managed similarly to high-grade conventional osteosarcoma, including MAP chemotherapy and surgical resection.

Comprehensive staging is mandatory before initiating treatment to define disease extent, assess resectability, and determine systemic spread — all of which fundamentally influence treatment approach and prognosis.

Enneking Surgical Staging System: The most widely used orthopaedic staging system for musculoskeletal sarcomas, introduced by Enneking et al. in 1980, classifies tumours based on histological grade (G), anatomical setting (T: intracompartmental vs extracompartmental), and metastasis (M):

• Stage IA: Low grade (G1), intracompartmental (T1), no metastasis (M0)
• Stage IB: Low grade (G1), extracompartmental (T2), M0
• Stage IIA: High grade (G2), intracompartmental (T1), M0
• Stage IIB: High grade (G2), extracompartmental (T2), M0 — the stage of most conventional osteosarcomas at presentation
• Stage III: Any grade, any local extent, with regional or distant metastasis (M1)

Staging workup investigations:

• MRI of the primary site: Defines intramedullary extent, skip lesions, soft tissue involvement, and neurovascular proximity — essential for surgical planning
• CT chest: Pulmonary metastases are the most common site of distant spread (approximately 15–20% at presentation)
• Bone scan (Tc-99m) or FDG-PET/CT: Detection of skeletal metastases or multifocal disease
• Open or core needle biopsy: Mandatory for histological diagnosis; must be performed by the treating surgeon to ensure the biopsy tract is within the planned resection margin
• Laboratory tests: Serum alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) are prognostic markers; elevated values correlate with inferior outcome

Patient eligibility for curative-intent treatment depends on absence of unresectable metastatic disease (or controlled oligometastatic disease), adequate cardiopulmonary reserve to tolerate intensive chemotherapy, and multidisciplinary team (MDT) agreement on surgical resectability.

Modern treatment of high-grade osteosarcoma and UPS-B follows a standardised neoadjuvant chemotherapy — surgery — adjuvant chemotherapy paradigm, with surgery adapted to the individual tumour site and patient anatomy.

MAP Chemotherapy Protocol: The standard systemic chemotherapy regimen is the MAP protocol, incorporating three agents:

• High-dose methotrexate (HD-MTX): 8–12 g/m² intravenous infusion with leucovorin rescue; inhibits dihydrofolate reductase, disrupting folate-dependent DNA synthesis in rapidly dividing cells
• Doxorubicin (adriamycin): 75 mg/m² per cycle; anthracycline antibiotic causing DNA intercalation and topoisomerase II inhibition; cardiotoxicity monitoring (echocardiography, cumulative dose limits) is mandatory
• Cisplatin: 100–120 mg/m² per cycle; platinum compound causing intrastrand DNA crosslinks; requires intensive hydration to prevent nephrotoxicity; ototoxicity monitoring (audiometry) required

Neoadjuvant chemotherapy (2–3 cycles prior to surgery) reduces tumour size, facilitates limb-salvage surgery, and enables critical assessment of Huvos histological response — the percentage of viable tumour cells remaining in the resected specimen:

• Huvos Grade I: Little or no effect (<50% necrosis)
• Huvos Grade II: Partial response (50–89% necrosis)
• Huvos Grade III: Good response (90–99% necrosis)
• Huvos Grade IV: Complete pathological response (100% necrosis, no viable tumour)

Grades III and IV are considered ‘good responders’ and correlate with significantly superior 5-year survival (approximately 75% vs 45% for poor responders).

Surgical options:

• Limb-salvage surgery: The standard surgical approach in over 85% of cases at specialist centres. Involves wide en-bloc resection of the tumour with a margin of normal tissue, followed by skeletal reconstruction using modular endoprostheses, allograft, autograft, or combined biological-prosthetic constructs.
• Amputation: Reserved for cases where limb salvage would yield inadequate surgical margins, when neurovascular involvement is unresectable, for pathological fracture in certain anatomical settings, or when the patient has an unreconstructable limb following inadequate neoadjuvant response.
• Pulmonary metastasectomy: For patients with resectable pulmonary metastases (most common distant site), aggressive surgical resection of lung lesions — including repeated thoracotomies for multiple metastases — is associated with long-term survival in 20–40% of selected patients and is considered standard practice in expert sarcoma centres.

The integration of neoadjuvant chemotherapy with surgical resection has transformed osteosarcoma outcomes and established a model of multidisciplinary sarcoma care that yields the best results when delivered at specialist centres.

Dramatically improved survival with chemotherapy: Prior to the introduction of multiagent chemotherapy in the 1970s, the 5-year survival for osteosarcoma was approximately 10–20%, even after amputation, because of undetected micrometastatic disease. With MAP-based neoadjuvant and adjuvant chemotherapy, 5-year overall survival for localised high-grade osteosarcoma now ranges from 60–75% in most published series.

High limb-salvage rates without compromising survival: Large case series and multicentre studies confirm that, in expert hands, limb-salvage surgery achieves equivalent overall and disease-free survival to amputation, with substantially better functional and quality-of-life outcomes. Patients undergoing limb salvage retain functional extremities enabling near-normal ambulation, occupational participation, and psychological well-being.

Huvos grading as a therapeutic response biomarker: Histological evaluation of chemotherapy response in the resected specimen provides an invaluable prognostic indicator and biological audit of neoadjuvant efficacy. Good responders (Huvos III/IV) benefit from continued maintenance of the same MAP regimen; poor responders may be candidates for intensification or clinical trials of alternative agents.

Pulmonary metastasectomy with curative potential: Aggressive surgical management of oligometastatic pulmonary disease — including repeated thoracotomies — can achieve long-term survival in a meaningful proportion of patients with relapsed or initially metastatic disease, a clinical strategy not available in most other solid tumour malignancies with comparable frequency of metastatic presentation.

Specialist centre advantage: Sarcoma cases managed at designated specialist centres with dedicated sarcoma MDTs achieve superior survival outcomes to those treated in non-specialist settings — a finding replicated across international health systems and underpinning referral guidelines.

Treatment of osteosarcoma and UPS-B carries significant toxicity from both chemotherapy and surgery. Open discussion of these risks within the MDT and with the patient and family is a cornerstone of informed consent and shared decision-making.

Chemotherapy toxicities:

• Doxorubicin cardiotoxicity: Cumulative anthracycline exposure carries a dose-dependent risk of cardiomyopathy (dilated, potentially progressive). Echocardiographic monitoring before each cycle and at treatment completion is mandatory. Total cumulative doxorubicin dose is carefully tracked.
• Cisplatin nephrotoxicity: Irreversible tubular damage can occur, particularly with repeated cycles. Aggressive pre- and post-hydration protocols are required. Renal function (GFR) is monitored throughout treatment.
• Cisplatin ototoxicity: Sensorineural hearing loss, particularly in high-frequency ranges, occurs in 20–40% of patients receiving cumulative cisplatin doses used in MAP therapy. Audiometric testing is performed before and during treatment. Loss of hearing is generally irreversible.
• High-dose methotrexate toxicity: Risk of mucositis, hepatotoxicity, renal impairment (methotrexate is renally excreted), and bone marrow suppression. Careful leucovorin rescue protocols and close monitoring of methotrexate serum levels are required.
• Myelosuppression and infection: All three MAP agents cause bone marrow suppression. Febrile neutropenia is a serious complication requiring prompt hospitalisation and IV antibiotics. G-CSF support is routinely used to reduce neutropenic periods.

Surgical risks:

• Limb-salvage complications: Include wound infection, deep prosthetic infection (requiring device removal or revision), aseptic loosening, periprosthetic fracture, and implant mechanical failure requiring revision surgery. Growing children may require multiple lengthening procedures or endoprosthesis revisions as the unaffected limb grows.
• Local recurrence: Occurs in approximately 5–10% of limb-salvage cases; requires radical salvage surgery (amputation in most instances).
• Amputation morbidity: Where amputation is required, phantom limb pain, prosthetic limb fitting challenges, and psychological adjustment require specialist rehabilitation.

Long-term, structured surveillance following completion of curative-intent treatment is essential for the early detection of recurrent disease and management of late treatment effects.

Oncological surveillance:

• Chest CT: Performed every 3 months for the first 2 years, then every 6 months to 5 years, and annually thereafter. The lung is the most frequent site of metastatic relapse, and early detection of resectable pulmonary metastases enables curative pulmonary metastasectomy in selected patients.
• Local imaging (MRI of operative site): Every 3–6 months for 2 years to detect local recurrence. Plain radiographs of the operated extremity are used for prosthetic surveillance.
• Bone scan or FDG-PET/CT: Annually or when symptomatic to detect skeletal metastases.
• Serum tumour markers (ALP, LDH): Monitored at each visit; elevation may precede radiographic evidence of relapse.

Late effects monitoring:

• Cardiac function: Annual echocardiography is recommended for at least 5–10 years following doxorubicin therapy due to the risk of late-onset cardiomyopathy, particularly with anthracycline exposure during adolescent cardiac development.
• Renal function: Annual GFR estimation following cisplatin exposure; monitor for proteinuria and hypertension as markers of chronic nephrotoxicity.
• Hearing assessment: Annual audiometry for those with documented cisplatin-related hearing loss to guide audiological support (hearing aids).
• Endocrine and fertility: Gonadotoxic chemotherapy may affect fertility; baseline sperm banking in post-pubertal males and fertility preservation counselling in females should be offered before treatment commences.

Functional rehabilitation: Physiotherapy and occupational therapy following limb-salvage surgery are essential to maximise function. Return to sport and activity goals should be discussed with the patient and physio team during active rehabilitation.

Treatment of osteosarcoma and UPS-B is resource-intensive, reflecting the complexity of multiagent chemotherapy, surgical reconstruction, prolonged hospitalisation, and multidisciplinary monitoring required throughout the treatment pathway.

Chemotherapy costs: High-dose methotrexate administration requires inpatient admission for infusion, leucovorin rescue, and pharmacokinetic monitoring over 24–48 hours per cycle. MAP chemotherapy spanning 6–9 months (neoadjuvant plus adjuvant phases) generates substantial hospitalisation, nursing, pharmacy, and laboratory costs. In the United States, a full MAP chemotherapy course without insurance may cost USD 150,000–400,000, though insurance coverage typically applies for established oncology regimens.

Surgical and prosthetic costs: Limb-salvage surgery with modular endoprosthetic reconstruction involves implant costs (USD 30,000–80,000 per custom or modular prosthesis), operating theatre time, intensive care unit admission, and extended hospital stay. Growing children may require additional procedures for limb length equalisation.

Medical tourism for bone sarcoma: Specialist sarcoma centres in India (Tata Memorial Hospital Mumbai, AIIMS Delhi), South Korea, Singapore, and Turkey offer internationally accredited oncological and orthopaedic sarcoma care at substantially lower cost — often 40–70% below US or UK prices. These destinations maintain dedicated sarcoma MDTs, pathology expertise, and modern endoprosthetic implant libraries. MyMedicPlus can assist in identifying and facilitating referrals to accredited centres.

Public health systems: In countries with universal healthcare (UK NHS, Canada, Australia), osteosarcoma treatment is covered without direct patient cost for citizens. Specialist sarcoma centres (e.g., Royal National Orthopaedic Hospital in the UK) provide MDT-coordinated care. Wait times for tertiary sarcoma referral may influence some patients to seek treatment abroad or in the private sector.

Rehabilitation and prosthetic follow-up: Long-term physiotherapy, prosthetic device maintenance, and surveillance imaging contribute ongoing costs extending well beyond the active treatment phase.

While the MAP chemotherapy — limb-salvage surgery paradigm remains standard of care for resectable osteosarcoma, several alternative and emerging approaches are relevant for specific clinical scenarios.

Alternative surgical approaches:

• Rotationplasty (Van Nes procedure): For tumours of the distal femur or proximal tibia in growing children, the leg below the knee is rotated 180° and fused to the remaining femur, so the ankle joint functions as a knee joint. Provides excellent long-term function and durability compared to endoprostheses in children; the cosmetic appearance requires psychological preparation.
• Allograft reconstruction: Use of donor bone allografts for skeletal reconstruction avoids some of the mechanical failure risks of endoprostheses but carries risks of non-union, fracture, and infection.

Radiation therapy: High-grade osteosarcoma is inherently radioresistant due to high-activity DNA repair mechanisms, and radiation plays no role as a curative modality in primary osteosarcoma. It may be used for palliation in unresectable or metastatic disease, particularly for spinal or pelvic primaries where surgery is not feasible. Particle beam therapy (proton or carbon ion) is under investigation for selected anatomical sites.

Emerging systemic therapies:

• Mifamurtide (MTP-PE, L-MTP-PE): An immunomodulator stimulating macrophage-mediated tumour cytotoxicity; approved in Europe (but not the US) as an adjunct to MAP chemotherapy in non-metastatic osteosarcoma following the EURAMOS-1 trial showing improved overall survival in the subgroup analysis.
• Immune checkpoint inhibitors: PD-1/PD-L1 inhibitors (pembrolizumab, nivolumab) have shown modest single-agent activity in relapsed/refractory osteosarcoma in early-phase trials; investigation in combination regimens is ongoing.
• Targeted agents: VEGFR inhibitors (sorafenib, regorafenib), CDK4/6 inhibitors, and IGF-1R antagonists have been explored; sorafenib shows progression-free survival benefit in relapsed osteosarcoma.
• CAR-T cell therapy: Early-phase trials targeting HER2 and GD2 antigens expressed on osteosarcoma cells are underway at specialist centres.

Clinical trials: All patients with osteosarcoma or UPS-B at diagnosis should be evaluated for participation in an open clinical trial. The EURAMOS and COSS cooperative group trials have defined current standard of care and new trials continue to test intensification and novel agent strategies.